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Abstract
Background: Serological testing based on different antibody types are an alternative method being used to
diagnose SARS-CoV-2 and has the potential of having higher diagnostic accuracy compared to the current gold
standard rRT-PCR. Therefore, the objective of this review was to evaluate the diagnostic accuracy of IgG and IgM
based point-of-care (POC) lateral flow immunoassay (LFIA), chemiluminescence enzyme immunoassay (CLIA),
fluorescence enzyme-linked immunoassay (FIA) and ELISA systems that detect SARS-CoV-2 antigens.
Method: A systematic literature search was carried out in PubMed, Medline complete and MedRxiv. Studies
evaluating the diagnostic accuracy of serological assays for SARS-CoV-2 were eligible. Study selection and data-
extraction were performed by two authors independently. QUADAS-2 checklist tool was used to assess the quality
of the studies. The bivariate model and the hierarchical summary receiver operating characteristic curve model
were performed to evaluate the diagnostic accuracy of the serological tests. Subgroup meta-analysis was performed
to explore the heterogeneity.
Results: The pooled sensitivity for IgG (n = 17), IgM (n = 16) and IgG-IgM (n = 24) based LFIA tests were
0.5856, 0.4637 and 0.6886, respectively compared to rRT-PCR method. The pooled sensitivity for IgG (n = 9)
and IgM (n = 10) based CLIA tests were 0.9311 and 0.8516, respectively compared to rRT-PCR. The pooled
sensitivity the IgG (n = 10), IgM (n = 11) and IgG-IgM (n = 5) based ELISA tests were 0.8292, 0.8388 and
0.8531 respectively compared to rRT-PCR. All tests displayed high specificities ranging from 0.9693 to 0.9991.
Amongst the evaluated tests, IgG based CLIA expressed the highest sensitivity signifying its accurate detection
of the largest proportion of infections identified by rRT-PCR. ELISA and CLIA tests performed better in terms
of sensitivity compared to LFIA. IgG based tests performed better compared to IgM except for the ELISA.
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Conclusions: We report that IgG-IgM based ELISA tests have the best overall diagnostic test accuracy.
Moreover, irrespective of the method, a combined IgG/IgM test seems to be a better choice in terms of
sensitivity than measuring either antibody type independently. Given the poor performances of the current
LFIA devices, there is a need for more research on the development of highly sensitivity and specific POC
LFIA that are adequate for most individual patient applications and attractive for large sero-prevalence studies.
Systematic review registration: PROSPERO CRD42020179112
Keywords: Serology, COVID-19, SARS-CoV2, rRT-PCR, IgG, IgM, Specificity, Sensitivity
Introduction
Coronavirus disease 2019 (COVID-19) is a major contagious
pandemic of respiratory disease caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which is
also known as novel (new) coronavirus 2019-nCoV [1–3].
The first COVID-19 cases were identified in December 2019
from Wuhan, Hubei Province, China [4]. On November 18
2020, according to the European Centre for Disease Preven-
tion and Control, COVID-19 Situation update, there were
55,743,951 confirmed cases and 1,339,436 deaths reported
worldwide [5]. Although the COVID-19 clinical features are
not yet fully known and understood, clinicians have reported
clinical manifestations that range from asymptomatic
cases to patients with mild and severe respiratory illness,
with or without pneumonia, fever, cough and shortness of
breath. Older people (>65 years) and people of all ages
with severe chronic medical conditions such as lung dis-
ease, heart disease and diabetes seem to have a higher risk
of succumbing to severe COVID-19 illness [6].
Early and accurate diagnostic testing for COVID-19 is
critical for tracking the SARS-CoV-2, understanding the
virus epidemiology, informing case management,
suppressing transmission and for quarantine purposes [7,
8]. The standard diagnostic confirmatory test for COVID-
19 is based on the detection of nucleic acids of SARS-
CoV-2 by nucleic acid amplification tests, such as real-
time reverse-transcriptase polymerase chain reaction
(rRT-PCR). The test identifies viral nucleic acids when
present in sufficient quantity in sputum, throat swabs and
secretions of the lower respiratory tract. In some patients,
SARS-CoV-2 RNA detection in blood and oral fluid speci-
mens has been reported; however, limited data is available
on adequacy of SARS-CoV-2 detection in these specimens
[9]. The rRT-PCR test is time consuming as it takes be-
tween 4 to 6 h for completion. It requires expensive spe-
cialist equipment, skilled laboratory personal for sample
preparation and testing and PCR reagents, creating diag-
nostic delays and limiting use in real-life situations when
rapid diagnosis is required for fast intervention decisions.
Therefore, less expensive and easy implementable tests
are required for SARS-CoV-2 detection. Another limita-
tion of using rRT-PCR involves the use of swabs from the
upper respiratory tract which can be falsely diagnosed as
negative due to the poor quality of the sample or acquir-
ing the sample at an incorrect timeframe; notably, viral
load in upper respiratory tract secretions peak in the first
week of symptoms but may decline below the limit of de-
tection in patients presenting late with symptoms [8, 10–
12]. Missing the time-window of viral replication may also
provide false negative results. Moreover, after a variable
period of time, one expects the rRT-PCR result to become
negative due to cessation of viral shedding [13].
False-negative rRT-PCR results are common during
diagnosis of SARS-CoV-2. The Fever Clinic of the
Beijing Haidian Hospital collected data from January
2020 which indicated that only two out of ten nega-
tive cases diagnosed by rRT-PCR test were confirmed
to be true positive for COVID-19. This yielded an ap-
proximately 20% false-negative rate of rRT-PCR [12].
Zhang et al. also showed that the current strategy for
the detection of viral RNA in oral swabs used for
SARS-CoV-2 diagnosis is not 100% accurate. The
presence of the virus has been detected in anal swabs
or blood samples of patients whilst their oral swabs
diagnosis reports a negative result. This observation
implies that a patient cannot be discharged based
purely on oral swab samples being negative [14].
A false negative diagnosis may have grave conse-
quences, especially at this stage of the COVID-19
pandemic by allowing SARS-CoV-2 infected patients
to spread the infection thereby hampering the efforts
to contain the spread of the virus [8]. Additional
screening methods that can detect the presence of in-
fection despite lower viral titres are highly beneficial
to ensure timely diagnosis of all COVID-19 patients.
Detection of serum specific anti-SARS-CoV-2 anti-
bodies, both immunoglobulin G (IgG) and M (IgM),
which are produced rapidly after the infection pro-
vides an alternative highly sensitive and accurate solu-
tion and compensates for the limitations of rRT-PCR.
The serological methods could also be a more prac-
tical alternative to chest CT [8, 15, 16]. Immuno-
globulin G antibodies permit the use of serological
tools to better understand the overall rate of COVID-
19 infections including the rate of asymptomatic in-
fections [8].
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However, the dynamics of blood or serum antibodies in
the cases of COVID-19 are not well evaluated. Currently,
the serological dynamics of COVID-19 patients remain
limited. Also, before diagnostic assays are widely deployed,
their performance characteristics need to be evaluated.
Therefore, the objective of this review was to evaluate the
diagnostic accuracy of IgG and IgM (together or separ-
ately) based point-of-care (POC) lateral flow immunoassay
(LFIA), chemiluminescence enzyme immunoassay (CLIA),
fluorescence enzyme-linked immunoassay (FIA) and
enzyme-linked immunosorbent assay (ELISA) to detect
antigens against SARS-CoV-2.
Review questions
The primary research question of this systematic review
was ‘What is the diagnostic accuracy of antibody ser-
ology tests for COVID-19 using the bivariate model and
the hierarchical summary receiver operating characteris-
tic curve (HSROC) model?’
Materials and methods
We conducted a systematic review and meta-analysis in
accordance with the recommendations of the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses of Diagnostic test accuracy (PRISMA-DTA) [17]
(Additional file 1). We used the Cochrane recommenda-
tions to report systematic reviews and meta-analyses of
studies on diagnostic accuracy [18]. We also used proto-
cols from published systematic and meta-analysis reviews
to develop our protocol [19–22]. The developed system-
atic review protocol was registered in the International
Prospective Register of Systematic Reviews registration
number CRD42020179112.
Eligibility criteria
Cross-sectional studies would be the ideal study type to
answer our review questions. However, as we anticipated
that serological diagnosis cross-sectional studies for
COVID-19 would be very sparse, we decided to include
case-control studies. The inclusion criteria comprised
studies in which the study population (n≥10) were sub-
jected to COVID-19 rRT-PCR testing or genetic sequen-
cing as the reference standards and either one or all of the
following serological tests; point-of-care (POC), lateral
flow immunoassay (LFIA), chemiluminescence enzyme
immunoassay (CLIA), fluorescence immunoassays (FIA)
and enzyme-linked immunoassay (ELISA). Studies that
used chest CT images, epidemiological history, well-
defined clinical features accompanied by rRT-PCR as a
reference standard were included. The diagnostic accuracy
of the tests was defined as the primary outcome. Original
studies were included without restriction based on lan-
guage or geographical location. We included studies be-
tween 1 January 2020, and 27 April 2020. Animal studies,
in vitro-based studies and survey studies investigating
seroprevalence were excluded from the study.
Information sources and search strategies
The following databases were searched for studies: MEDL
INE Complete (EBSCO), PubMed, and MedRxiv (a
preprint server for health sciences which distributes
complete but unpublished manuscripts). We performed
the search strategy on studies dated until 29 April 2020.
The data bases were searched using predefined keywords:
COVID-19 and serologic test and their synonyms.
Appendix 1 illustrates the search strategy for PubMed,
which was adapted for the other data bases. Additional
studies were identified by contacting experts in the field
and by searching reference lists from primary studies,
review articles and textbook chapters.
Study selection and data extraction
Two authors (AV and HM) assessed the titles identi-
fied by the search, excluding those obviously irrele-
vant to the serological diagnosis of COVID-19.
Letters, review articles and articles clearly irrelevant
based on examination of the abstract and other notes
and duplicates were excluded next. The eligibility of
the remaining potentially relevant articles was judged
on full-text publications.
Data extraction was conducted independently by two
authors (AV and HM) to avoid bias and discrepancies
and was resolved by discussion. Where an agreement
could not be reached, a third author was consulted.
Where it remained unclear whether a study is eligible
for inclusion, it was then excluded. Whilst extracting
data, authors also had to decide whether a study was a
case-control or a cross-sectional study. The following
data were extracted.
 Study authors and publication year
 Study design
 Case definition (inclusion/exclusion criteria)
 Participant demographics
 Reference standard (including criteria for positive
test)
 Index tests [cutoff values (prespecified or not) and
whether the test was a commercial of in-house test]
 Geographical location of data collection
 Index/reference time interval
 Distribution of severity of disease in those with
target condition
 Other diagnoses in those without target condition
 Numbers of TPs, FNs, FPs and FNs
Other considerations and exclusion criteria
Studies, from which a 2×2 table containing true posi-
tives, false positives, false negatives and true negatives
Vengesai et al. Systematic Reviews          (2021) 10:155 Page 3 of 23
could not be drawn, were excluded. Furthermore, studies
that were too unspecific in their reporting to ensure that
they fulfilled the above criteria, were excluded.
Assessment of methodological quality
The QUADAS-2 tool was used to assess the methodo-
logical quality of all studies included in this systematic re-
view [23]. QUADAS-2 consists of four key domains:
patient selection, index test, reference standard and flow
and timing. We assessed all domains for risk of bias
(ROB) potential and the first three domains for applicabil-
ity concerns. Risk of bias was judged as ‘low,’ ‘high’ or
‘unclear’. Details are shown in Appendix 2. Two review
authors (AV and HM) independently completed
QUADAS-2. The divergences were resolved by consensus
amongst the researchers.
Statistical analysis and data synthesis
Diagnostic accuracy
For each study, we constructed 2 × 2 tables for true
positives (TP), true negatives (TN), false positives (FP) and
false negatives (FN). Where only sensitivity and specificity
estimates were reported, we derived the two-by-two table
from the reported data. We constructed forest plots dis-
playing sensitivity and specificity of the index tests from
contingency tables assuming that the reference method
was 100% sensitive and specific. Data were entered into
the Review Manager (RevMan) software for Windows
v.5.3 (Cochrane Collaboration, Copenhagen, Denmark)
and forest plots were created with 95% confidence interval
(CI) for sensitivity and specificity for each study.
Studies were submitted to meta-analysis when three
conditions were met: sample size was greater than 20;
sensitivity and specificity were available for the index
and control group was included in the analysis. We
used the two recommended random-effects hierarch-
ical methods: the bivariate model and the hierarchical
summary receiver operating characteristic (HSROC)
model for performing the meta-analysis. The focus of
the bivariate model is estimation of a summary point
(summary sensitivity and specificity). HSROC model
is on estimating an SROC curve [24]. The summary
estimates of sensitivity and specificity and 95% CI and
the HSROC were calculated using OpenMeta-Analyst
for windows 10 (open-source, cross-platform for
advanced meta-analysis).
Investigations of heterogeneity
We investigated heterogeneity by adding antigen type
as the covariate. The following approach was taken:
Firstly, the variation in accuracy between IgG or IgM
or IgG-IgM based LFIA, CLIA and ELISA serological
testing was analysed (Table 2). Then, the effect of the
antigen type was investigated using subgroup meta-
analysis in OpenMeta-analyst. I^2 values close to 0% were
considered as having no heterogeneity between studies;
values close to 25 %, low heterogeneity; values close to
50%, moderate heterogeneity and values close to 75%, high
heterogeneity between studies [25].
Assessment of publication bias
In this review, we did not assess for reporting bias.
The studies included in our meta-analysis showed a
lot of heterogeneity; therefore, assessments for report-
ing bias may not yield conclusive results. This was
adopted from the approach used by Ochodo et al.
[26].
Test sensitivity by time since onset of symptoms
We stratified data by days since COVID-19 symptom
onset to specimen collection. Then, we constructed for-
est plots (95 % CI) displaying test sensitivity by time
since onset of symptoms using the RevMan software for




The results of the search and selection process are pre-
sented in Fig. 1. A total of 202 articles were identified.
Amongst these, 40 were MedRxiv preprints and 162
were fully published articles from MEDLINE Complete
(EBSCO) and PubMed. Two articles were identified from
other sources for example manual search. After abstract/
title exclusion and removing duplicates, 74 articles were
submitted to full-text screening and 31 of these were in-
cluded for the systematic review. Most articles were ex-
cluded because they did not present sufficient data
hence it was not possible to extract data to construct 2
× 2 table and 1 article was excluded because it was only
available in Chinese. A total of 29 articles describing the
results of 99 independent studies/data sets (19, 23 and
57 investigating LFIA, CLIA and ELISA respectively)
were eligible for the meta-analysis.
Characteristics of the studies
The general characteristics of the included articles
are presented in Table 1. All the published articles
(n = 14) included in the review were published in
2020 because COVID-19 is an emerging disease. The
17 unpublished articles were MedRxiv preprints
which have been submitted to different journals for
publication. Twenty five articles included in the re-
view had a case-control design, comparing a group
of well-defined cases with a group of healthy con-
trols or controls with diseases or COVID-19 rRT-
PCR negative patients, and only six studies were
cross sectional studies. One study had no control
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group and was excluded in the meta-analysis [27].
Most of the studies (n = 22) were conducted in
China where the COVID-19 pandemic began and 3
studies were conducted in Italy whilst, USA whilst
UK, Denmark, Germany, Spain and Japan each con-
ducted one study.
Most articles (n = 26) included in the review clearly
stated that the gold standard nucleic acid tests (rRT-
PCR or deep sequencing) were used as the reference
standard. However, five articles used a combination of
epidemiological risk, clinical features, chest CT images
and rRT-PCR. In one article, the reference standard used
was not stated but all the patients in the study were
COVID-19 patients [38].
Point-of-care (POC) lateral flow immunoassays
(LFIA) were used in 14 articles, CLIA were used in 9
articles and ELISA were used in 13 articles. We did
not identify articles using FIA that met our inclusion
criteria. One study did not specify the serological
assay used and it was excluded from the review [31].
One study used a LIPS which is performed in solu-
tion, thus maintaining the native antigen conform-
ation [54]. Most of the serological assay test kits were
commercial (n = 21) and 12 were in-house. Three
SARS-CoV-2 antigens, Spike protein (S), nucleocapsid
protein (N) and envelope protein (E) were used to-
gether or separately in studies included in the review.
The spike protein and nucleocapsid were used as the
antigen in 9 articles and 6 articles respectively. Five
articles used both S and N as the antigens separately.
In 3 articles, S and N antigens (S-N) were used to-
gether as the antigen. In 1 article, N and E antigens
(N-E) were used together as the antigen. In 7 articles,
the name of antigen used was not given.
Fig. 1 PRISMA flow diagram for selection of articles for meta-analysis
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Methodological quality of included studies
The methodological quality of the included studies
for the IgG or IgM or IgG-IgM based LFIA, CLIA
and ELISA summarised across all studies are shown
in Figs. 2b, 3b and 4b. Figures 2a, 3a and 4a show for
the risk of bias and applicability concerns summary
results for the LFIA, CLIA and ELISA individual
studies respectively. None of the studies included in
Fig. 2 LFIA methodological quality summary table and graph. a Risk of bias and applicability concerns summary: review authors’ judgements
about each domain for each included study. b QUADAS-2 bias assessment and QUADAS-2 applicability assessment item presented as
percentages across all included studies. On the left, risk of bias graph and on the right applicability concerns graph. c Risk of bias and
applicability concerns summary: review authors. Low, low risk of bias; high, high risk of bias; unclear, bias is unclear
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this review had low risk of bias in all four QUADAS-
2 domains. Generally, case control studies were of
high risk of bias and high concern in the patients and
timing and flow domains and cross sectional studies
were of low risk of bias and low concern in all
domains.
Patient selection domain
Generally, most studies included were at risk of bias
and had high concerns regarding applicability. Studies
were mostly case control studies and they did not in-
clude a consecutive or random series of participants
implying that the patients that were included are not
representative for clinical use. All thirteen ELISA
studies were at high risk of bias and had high con-
cerns regarding applicability. For CLIA, all the 9 stud-
ies included had high risk of bias and only 1 cross
sectional study had low applicability concerns. Gener-
ally, LFIA had more studies (n = 4) with low risk of
bias and applicability concerns in the patient selection
domain because there were 4 LFIA cross-sectional
studies.
Index test domain
The LFIA studies had a high risk of bias (9/14) and
high applicability concerns (12/14) in the index test
domain. The high risk of bias was due to no blinding
between the index test and the reference test. The
high applicability concerns were due to tests using
serum or plasma instead of whole blood which would
make the test less amenable to use at the point of
care. The CLIA and ELISA studies generally had a
low risk of bias (6/9 and 8/13 respectively). This was
because most studies were automated and had a pre-
Fig. 3 CLIA methodological quality summary table and graph. a Risk of bias and applicability concerns summary: review authors’ judgements
about each domain for each included study. b QUADAS-2 bias assessment and QUADAS-2 applicability assessment item presented as
percentages across all included studies. On the left, risk of bias graph and on the right applicability concerns graph. c Risk of bias and
applicability concerns summary: review authors. Low, low risk of bias; high, high risk of bias; unclear, bias is unclear
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specified threshold (cut-off value to decide whether a
test is positive or negative). The studies that had high
risk of bias did not have a pre-specified threshold.
Likewise, CLIA and ELISA studies generally had low
applicability concerns in the index test domain (5/9
and 8/13 respectively) because they used commercial
index tests.
Reference standard domain
Like the index test domain, studies generally had a low
risk of bias (10/14, 8/9 and 10/13 for LFIA, CLIA and
ELISA respectively) in the reference standard domain.
Generally, the studies were of low applicability concern,
10/14, 8/9 and 11/13 for LFIA, CLIA and ELISA
respectively.
Flow and timing domain
All the CLIA (n = 9) and ELISA (n = 13) studies
were at high risk of bias in the flow and timing
domain. These studies were all case control studies.
Most of the LFIA studies were also at a high risk of
bias; however, 4 cross sectional LFIA studies were at
low risk of bias.
Fig. 4 ELISA methodological quality summary table and graph. a Risk of bias and applicability concerns summary: review authors’ judgements
about each domain for each included study. b QUADAS-2 bias assessment and QUADAS-2 applicability assessment item presented as
percentages across all included studies. On the left, risk of bias graph and on the right applicability concerns graph. c Risk of bias and
applicability concerns summary: review authors. Low, low risk of bias; high, high risk of bias; unclear, bias is unclear




Fig. 5 Forest plot of sensitivity, specificity and heterogeneity of serological LFIA diagnosis of COVID-19. a Forest plot for the IgG LFIA. b Forest
plot for the IgM based LFIA. c Forest plot for the IgG-IgM based LFIA
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Quantitative synthesis and meta-analysis
Firstly, we considered performance of the LFIA de-
vices using rRT-PCR-confirmed cases as the reference
standard. The forest plots in Fig. 5 show the sensitiv-
ity, specificity range and heterogeneity for the three
IgG or IgM or IgG-IgM based LFIA detecting
COVID-19 across the included studies. Overall, the
sensitivity varied widely across studies in contrast to
the specificity which did not vary much except for 2
studies, Yunbao Pan, 2020, and Qiang Wang, 2020,
which had the lowest and second lowest specificities
respectively. Amongst the IgG based LFIA tests (n =
17), the sensitivity estimates ranged from 0.14 (95%
CI 0.09-0.21) (Imai, 2020) to 1.00 (95% CI 0.77-1.00)
(Qiang Wang, 2020) and specificity estimates ranged
from 0.41 (95% CI 0.21-0.64) (Yunbao Pan, 2020) to
1.00 (95% CI 0.97-1.00) (Bin Lou, 2020) (Fig. 5a). For
the IgM based LFIA tests (n = 16), the sensitivity es-
timates ranged from 0.05 (95% CI 0.01-0.18) Adams
(assay 4 to 1.00) (95% CI 0.77-1.00) (Qiang Wang,
2020) and specificity estimates ranged from 0.64 (95%
CI 0.41-0.83) (Yunbao Pan, 2020) to 1.00 (95% CI
0.94-1.00) (Adams assays 4 and 5) (Fig. 5b). For the
IgG-IgM based LFIA tests (n = 24), the sensitivity es-
timates ranged from 0.18 (95% CI 0.08-0.34) (Cassa-
niti, 2020) to 1.00 (95% CI 0.77-1.00) (Qiang Wang,
2020), with most of the studies having sensitivities
over 0.55 and specificity estimates ranged from 0.36
(95% CI 0.17-0.59) (Yunbao Pan, 2020) to 1.00 (95%




Fig. 6 Forest plot of sensitivity, specificity and heterogeneity of serological CLIA diagnosis of COVID-19. a Forest plot for the IgG CLIA. b Forest
plot for the IgM based CLIA. c Forest plot for the IgG-IgM based CLIA
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We then considered performance of the different IgG
or IgM or IgG-IgM based CLIA test using rRT-PCR-
confirmed cases as the reference standard (Fig. 6a, b and
c). Considering any positive result (IgM positive, IgG
positive or both), CLIA serological tests achieved sensi-
tivity ranging from 0.48 (95% CI 0.29-0.68%) (Yujiao Jin,
2020) to 1.00 (95% CI 0.79-1.00) with most studies being
between 0.80 and 1. The specificity was over 0.80 in
most tests except for 2 tests, one IgG based test and one
IgM based test which had the lowest 0.00 (95% CI 0.00-
0.009) and second lowest 0.15 (95% CI 0.06-0.30) speci-
ficities respectively.
Lastly, we evaluated the performance of the differ-
ent IgG or IgM or IgG-IgM based ELISA tests using
rRT-PCR-confirmed cases as the reference standard
(Fig. 7a, b and c). The sensitivities and specificities
were generally high, ranging from 0.80 to 1.00 and




Fig. 7 Forest plot of sensitivity, specificity and heterogeneity of serological ELISA diagnosis of COVID-19. a Forest plot for the IgG ELISA. b Forest
plot for the IgM based ELISA. c Forest plot for the IgG-IgM based ELISA
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ELISA tests (n = 10), the sensitivity estimates ranged
from 0.65 (95% CI 0.57-0.72) (Zhao, 2020) to 1.00
(95% CI 0.79-1.00) (Kai-Wang To, 2020) and specifi-
city estimates from 0.86 (95% CI 0.51-0.89) to 1.00
(95% CI 0.98-1.00) (Ling Zhong, 2020) (Fig. 7a). In
the IgM based tests (n = 11), the sensitivity and spe-
cificity in the individual studies ranged from 0.44
(95% CI 0.32-0.58) (Jie Xiang, 2020) to 1.00 (95% CI
0.77–1.00) (Qiang Wang, 2020) and 0.69 (95% CI
0.57-0.80) (Qiang Wang, 2020) to 1.00 (95% CI
0.99–1.00) (Ling Zhong, 2020), respectively (Fig. 7b).
The sensitivity across the 5 studies included in the
IgG-IgM based ELISA tests ranged from 0.80 (95%
CI 0.74-0.85) (Wanbing Liu, 2020) to 0.87 (95% CI
a b
c
Fig. 8 Summary ROC curves for the three antibody serological test groups. Every symbol reflects a 2 × 2 table, one for each test. One study may
have contributed more than one 2 × 2 table. The curves are shown for the different test types
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0.77-0.94) (Rongqing Zhao, 2020). On the other
hand, specificity across the 5 studies ranged from
0.97 (95% CI 0.92-0.99) (Lei Liu, 2020) to 1.00 (95%
CI 0.98-1.00) (Rongqing Zhao, 2020) (Fig. 7c).
We also constructed the SROC curves for all the three
antibody based serological tests (Fig. 8). However, we
did not calculate the area under the ROC (AUROC).
From the SROC, we visually assessed heterogeneity be-
tween the different tests. Diagonal line indicated useless
tests and the best tests were clustered further up to the
top left hand corner.
The bivariate model and the hierarchical summary
receiver operating characteristic curve (HSROC)
model were performed to evaluate the diagnostic
accuracy of the serological tests. The outputs of the
meta-analysis (bivariate and HSROC parameter
estimates, as well as the summary values of sensitiv-
ity and specificity) are presented in Table 2 and Fig.
9. The pooled sensitivity for the IgG, IgM and IgG-
IgM based LFIA tests were 0.5856, 0.4637 and
0.6886 respectively compared to rRT-PCR. The
pooled sensitivity for the IgG and IgM based CLIA
tests were 0.9311 and 0.8516 respectively compared
to rRT-PCR. The pooled sensitivity for the IgG, IgM
and IgG-IgM based ELISA tests were 0.8292,
0.0.8388 and 0.8531 respectively compared to rRT-
PCR. All the tests had high specificities ranging from
0.9693 to 0.9991 compared to rRT-PCR. The esti-
mated SROC curves for bivariate models are not
presented.
HSROCs were also used to visually access the over-
all performance of the diagnostic tests, to access the
overall diagnostic accuracy of the tests and to com-
pare the diagnostic accuracy of the different tests
used for diagnosing COVID-19 in the review (Fig. 9).
The overall diagnostic test accuracy was measured by
the proximity of the curve to the top left corner
which represents high sensitivity and specificity. The
closer the curve was to the upper left hand corner,
the better the diagnostic accuracy [55]. From Fig. 9, it
can be observed that ELISA and CLIA have better
diagnostic accuracy compared to LFIA and IgG-IgM
based ELISA tests have the best overall diagnostic test
accuracy. Of importance, it is noteworthy that in the
study the evidence base was too weak to definitively
state that one class of test was more accurate than
the other class of tests.
We identified one study (Burbelo, 2020) reporting
total antibody (Ab) based luciferase immunoprecipita-
tion assay system (LIPS) using N and S antigens with
sensitivities and specificities of 0.91 (95% CI 0.77-
0.99) and 1.00 (0.80-1.00) and 1.00 (0.92-1.00) and
1.00 (0.92-1.00) respectively. We also identified stud-
ies reporting other Ab based serological assays and
IgA based serological assays but results are not re-
ported in this review.
Heterogeneity investigations
Generally high overall I^2 values above 85%, which
indicate high heterogeneities, were observed for
both the sensitivities and specificities when we per-
formed antigen subgroup meta-analysis with the ex-
ception of IgG-IgM based ELISA. IgG-IgM based
ELISA had an overall sensitivity I^2 value of 52. 12% which
is considered moderate heterogeneity and overall specifi-
city I^2 value of 0% which is considered to be low hetero-
geneity. However, it should be noted that only 5 studies
were included for this subgroup meta-analysis. Overall I^2
values for sensitivities and specificities heterogeneities for
the antigen type subgroup meta-analysis are shown in
Table 3. We did not investigate heterogeneity for LFIA be-
cause most studies included in the review did not specify
the type of antigen they used in their serological tests.
Detailed results of heterogeneity for the different
antigen type sensitivities and specificities for each test
type and antibody type combination are presented in
Additional file 2.
Table 2 Summary estimates of test accuracy
Test type Antibody type Number of studies/tests Sensitivity (95% CI) Specificity (95% CI) Correlation
LFIA IgG 17 58.56 (43.97-71.79) 98.96 (95.61-99.76) −0.4454
CLIA IgG 9 93.11 (93.09-93.12) 97.57 (97.57-97.58 −0.511
ELISA IgG 10 82.92 (74.16-89.15) 99.48 (96.75-99.92) −0.1709
LFIA IgM 16 46.37 (30.16-0.6339) 97.34 (92.75-99.05) −0.7925
CLIA IgM 10 85.16 (73.56-0.9221) 96.93 (85.5-99.41) −0.7074
ELISA IgM 11 83.88 (0.7307-0.909) 99.91 (97.78-100) −0.7247
LFIA IgG-IgM 24 68.86 (58.78-77.42) 97.57 (94.66-98.92) 0.1011
CLIA IgG-IgM 3
ELISA IgG-IgM 5 85.31 (78.51-90.23) 99.01 (92.87-99.87) −0.6771
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Test sensitivity by time since onset of symptoms
Figure 10 shows forest plots for antibody positive rates for
IgG (25 tests), IgM (22 tests) and IgG-IgM (30 tests),
stratified by days since initial symptom onset to specimen
collection. The sensitivity of the serological tests generally
increased with increased time from symptoms onset.
Regardless of test method (ELISA or CLIA or LFIA), the
sensitivities for IgG and IgM based tests were generally
low in the first week (1-7 days) of symptom onset
followed by the second (7-14 days) and the sensitiv-
ities were generally highest in the third week or later
(>14 days) for each test. Data on specificity stratified
by specimen collection since symptom onset was not
available for all the studies.
Discussion
COVID-19 is a major healthcare challenge globally.
One key aspect of limiting SARS-CoV-2 spread is to
ensure early and accurate diagnosis of the viral in-
fection. In this study, we performed a meta-analysis
to evaluate the diagnostic accuracy of IgG and IgM
based serological assays offered to detect antigens
against rRT-PCR positive SARS-CoV-2 patients. The
meta-analysis showed that all serological assays
yielded high specificities ranging from 0.9693 (95%
CI 0.855-0.9941) to 0.9991 (95% CI 0.9778-1) in
comparison to rRT-PCR. Meta-analysis by Wang
et al., Bastos et al. and Deeks et al. observed similar
pooled specificities ranging from 0.95 (95% CI 0.91–
Fig. 9 Hierarchical summary receiver operating characteristic (HSROC) curve obtained using OpenMeta-Analyst. Every circle represents the
sensitivity and specificity estimates of individual studies in the meta-analysis, and the size of the circle reflects the sample size. The black dots
indicate summary points of sensitivity and specificity; HSROC curve is the line passing through summary point. The curve is the regression line
that summarises the overall diagnostic accuracy. a HSROC for IgG serological tests. b HSROC for IgM serological tests. c HSROC IgG-IgM
serological tests. 1, LFIA HSROC; 2, CLIA HSROC and 3, ELISA HSROC
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0.98) to 99.6 (97.3 to 99.9) [56–58]. The sensitivities
of all serological assays varied widely across studies.
COVID-19 serological assays rely on antibodies
binding to SARS-CoV-2 nucleocapsid protein, spike
protein or spike protein fragments (i.e. receptor
binding domain). Some tests or test devices even use
a combination of the N and S proteins and protein
fragments. This may have resulted in the inconsisten-
cies observed in the different serological assays [59].
Overall IgG-IgM based ELISA had superior diagnostic
accuracy with sensitivity and specificity of 0.8531
(95% CI 0.7851-0.9023) and 0.9991 (95% CI 0.9778-1).
IgG based CLIA had the highest sensitivity 0.9311
(95% CI 0.9309-0.9312). The pooled sensitivity results
are in agreement with other meta-analysis that
showed POC LFIA had lower sensitivities than CLIA
and ELISA within each antibody class [56–58]. How-
ever, it must be noted that a meta-analysis by Deeks
et al. found that for IgG and IgG-IgM, concentration
gradient immunoassay POC LFIA had higher pooled
sensitivity than ELISA [56].
Similar to other meta-analysis, IgM based sero-
logical assays had the lowest sensitivities compared
IgG based serological tests in each respective test
method [56–58]. Low antibody concentrations and es-
pecially timing of the IgM based serological assays
could potentially explain the low ability of the IgM
based tests to identify people infected with SARS-
CoV-2. Notably, immediately after a person is in-
fected, antibodies may not have been developed yet
or too late IgM antibodies may have decreased or dis-
appeared [60].
Generally combined IgG-IgM based serological as-
says seem to be a better choice in terms of sensitivity
than measuring either antibody type alone, though in
this review we did not estimate the pooled sensitivity
of the IgG-IgM based CLIA due to the limited num-
ber of studies. Subgroup meta-analysis using Open
Meta-Analyst showed that IgM based serological
assays that use the S antigen are more sensitive than
IgM based serological assays that used the N antigen-
based tests probably due to higher sensitivity and
earlier immune response to the S antigen [32]. How-
ever, subgroup meta-analysis showed that IgG based
serological assays that use N antigen are more sensi-
tive than IgG based serological assays that use S
antigen.
The sensitivity and specificity estimates from this re-
view were used to indicate the consequences of testing
when the test is being used in clinical practice. Preva-
lence estimates were calculated using metaDTA [61]
to predict how many patients in practice you would
expect to have true positive, false positive, true nega-
tive and false negative results for a given prevalence
based on the meta-analysis results giving the results
some clinical context. Using IgG-IgM based ELISA
test which had the best overall diagnostic accuracy as
an example, one can see that with 1000 patients and
a COVID-19 prevalence of 50%, we would expect 432
(95% CI 394-486) patients to test positive for SARS-
CoV-2, of which 427 (95% CI 393-451) will be true
positives (are diseased and test positive) and 5 (95%
CI 1-35) will be false positives (are not diseased but
test positive). We also noted 568 (95% CI 514-606)
patients test negative for COVID-19, of which 495
(95% CI 465-499) were true negatives (are not dis-
eased and test negative) and 73 (95% CI 49-107) were
false negatives (are diseased but test negative).
A prevalence of 1% and 1000 patients would mean
that 19 (95% CI 9-79) patients test positive for
SARS-CoV-2, 9 (95% CI 8-9) of these will be true
positives and 10 (95% CI 1-70) false positives and
981 (95% CI 921-991) patients will test negative for
SARS-COV-2, 980 (95% CI 920-989) of these will be
true negatives and 1 (95% CI 1-2) patient will be
false negative. This means that the false positive will
be treated for COVID-19 whilst they have another
disease, thus delaying their final diagnosis and










CLIA IgG 93.56% 86.5%
IgM 93.42% 95.17%
IgG-IgM
ELISA IgG 78.07% 84.97%
IgM 85.47% 90.08%
IgG-IgM 52.12% 0%
Vengesai et al. Systematic Reviews          (2021) 10:155 Page 17 of 23
Fig. 10 Forest plot of studies evaluating tests for detection of IgG, IgM and IgG-IgM according to days since COVID-19 symptom onset to
specimen collection. In brackets () are the number of days since symptom onset to specimen collection. Artron, Auto Bio CTK Biotech CTK
Biotech are test names all reported in a study by Lassaunire et al
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subsequent treatment. In the false-negatives,
COVID-19 diagnosis will be missed or delayed and
the patients will not be quarantined and they will
thus spread the SARS-CoV-2 to other patients in the
hospital/clinic. Nonetheless, despite calculations like
these providing insight in the consequences of test-
ing, they should be taken with caution.
Using the inferences for LIFA using the IgG-IgM
based test [sensitivity 0.6886 (0.5878-0.7742) and
specificity 0.9757 (0.9466-0.9892)]. We see that for
1000 patients and a COVID-19 prevalence of 50%,
we would expect 356 (95% CI 299-414) patients to
test positive for SARS-CoV-2, 324 (95% CI 294-387)
of which will be true positives and 12 (95% CI 5-27)
will be false positives. We would also expect 644
(95% CI 586-701) patients to test negative for the
COVID-19, 488 (95% CI 473-495) of which will be
true negatives and 156 (95% CI 113-206) are false
negatives. A prevalence of 1% and 1000 patients
would mean 31 (95% CI 16-62) patients test positive
for SARS-CoV-2, 7 (95% CI 6-8) of these will be
true positives and 24 (95% CI 10-54) false positives
and 969 (95% CI 938-984) patients to test negative
for COVID, 966 (95% CI 936-980) of these will be
true negatives and 3 (95% CI 2-4) are false negatives.
Compared to IgG-IgM based ELISA, the IgG-IgM
based LFIA has higher rates of false positives and
false negatives.
Limitation
Serological tests for SARS-CoV-2 have accuracy is-
sues that warrant attention. They measure specific
antibody responses which may take some weeks to
develop after disease onset reducing the sensitivity of
the assay. If blood samples were collected during the
early stage of the infection, they may produce false
negative results. They do not directly detect the
presence of the virus. Further, antibodies may be
present when SARS-CoV-2 is no longer present giv-
ing false positive case diagnosis. Moreover, since the
identity of the N protein of SARS-CoV-2 and SARS-
CoV reached up to 91.2%, there is probability of a
cross reaction between the N protein of SARS-CoV-
2 and antibodies against other human coronaviruses.
Other molecules including interferon, rheumatoid
factor and non-specific IgM may cause false positive
results [42].
Most studies included in the meta-analysis were case-
control studies. These may be easy to perform in a la-
boratory setting than cross-sectional designs, but their
results are less representative for clinical practice. The
performance of diagnostic tests very much depends on
the population in which the test is being used. Future
studies should therefore be prospective cross-sectional
studies including a consecutive sample of presenting
patients.
Index tests need to be evaluated to determine their
sensitivity and specificity, ideally by comparison with
a standard confirmatory test. An important limita-
tion with the rRT-PCR, the standard confirmatory
test for COVID-19 is the risk of false-negative re-
sults [62]. Two reviews of the accuracy of rRT-PCR
COVID-19 tests reported false negative rates of be-
tween 2% and 29%, based on negative rRT-PCR tests
which were positive on repeat rRT-PCR testing [63,
64]. False negative results of rRT-PCR tests can lead
decreased specificity of the serological tests (index
tests). The rRT-PCR negative results picked up as
positive tests by the serological tests will be treated
as false positives thereby lowering the specificity of
the serological tests. In order to reduce false-
negative results, Bastos et al. recommended that the
standard confirmatory test should consist of RT-PCR
performed on at least two consecutive specimens
and when possible it must include viral cultures
[57].
Conclusion
Given the poor performance of the current LFIA de-
vices, we recommend more research to develop highly
sensitivity and specific POC LFIA that are adequate
for most individual patient applications and attractive
for large seroprevalence studies. The use of CLIA and
ELISA for diagnosis has high sensitivity and is com-
parable to using rRT-PCR. They may be calibrated to
be specific for detecting and quantifying SARSCoV-2
IgM and IgG. More serological data should be col-
lected to elucidate the clinical and epidemiological
utility of IgG and IgM serological measurements to
detect symptomatic and asymptomatic cases of
COVID-19.
Appendix 1
Search strategy in PubMed
Search Query Items
found
#20 Search (((((COVID-19[Title/Abstract]) OR SARS-CoV-
2[Title/Abstract]) OR 2019-nCoV[Title/Abstract]) OR
Wuhan Coronavirus[Title/Abstract])) AND
(((((((((((((Serologic test) OR Serologic method) OR
Serological test) OR Serological method) OR Sero-
diagnosis) OR Immunodiagnosis) OR Immunological
test) OR Immunological method) OR Antibody de-
tection) OR Antigen detection) OR IgM) OR IgG) OR
Immunochromatography)
78
#19 Search ((((((((((((Serologic test) OR Serologic method)
OR Serological test) OR Serological method) OR
Serodiagnosis) OR Immunodiagnosis) OR
Immunological test) OR Immunological method) OR
822733
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Search strategy in PubMed (Continued)
Search Query Items
found
Antibody detection) OR Antigen detection) OR IgM)
OR IgG) OR Immunochromatography
#18 Search Immunochromatography 69624
#17 Search IgG 143941
#16 Search IgM 66041
#15 Search Antigen detection 82456
#14 Search Antibody detection 99123
#13 Search Immunological method 39637
#12 Search Immunological test 456120
#11 Search Immunodiagnosis 450622
#10 Search Serodiagnosis 184574
#9 Search Serological method 24322
#8 Search Serological test 191599
#7 Search Serologic method 16939
#6 Search Serologic test 184758
#5 Search (((COVID-19[Title/Abstract]) OR SARS-CoV-
2[Title/Abstract]) OR 2019-nCoV[Title/Abstract]) OR
Wuhan Coronavirus[Title/Abstract]
6734
#4 Search Wuhan Coronavirus[Title/Abstract] 14
#3 Search 2019-nCoV[Title/Abstract] 547
#2 Search SARS-CoV-2[Title/Abstract] 1898
#1 Search COVID-19[Title/Abstract] 5985
Appendix 2
Rating of QUADAS-2 items
1. Patient selection
1a. Risk of bias, signalling questions
 Was a case-control design avoided?
▪ Case-control designs, especially if they include
healthy controls, carry a high risk of bias.
Therefore, all case-control studies are automatic-
ally rated to be of high risk of bias in the overall
judgement.
 Was a consecutive or random sample of patients
enrolled?
 Did the study avoid inappropriate exclusions?
 Overall judgement:
▪ Case-control studies were always rated as having
a high risk of bias.
▪ Cross-sectional studies: only low risk of bias if
the other two signalling questions are answered
with ‘yes’. If one of the questions was answered
‘no’, then high risk of bias. Otherwise ‘unclear’.
1b. Concerns regarding applicability: this concerns the
extent to which the patients (both cases and controls)
that were included in a study are representative for the
patients which will receive these serology tests.
 Is there concern that the included patients do not
match the review question?
▪ All case-control studies are by default rated ‘high
concern’. All cross-sectional studies are by
default ‘low concern’, except when the used case
definition was not very clear.
2. Index test
2a. Risk of bias, signalling questions
 Were the index test results interpreted without
knowledge of the results of the reference standard?
 If a threshold was used, was it pre-specified? By
selecting the cut-off value with the highest
sensitivity and/or specificity, researchers
artificially optimise the accuracy of their tests,
which may lead to an overestimation of sensitivity and
specificity. POC LFIA threshold were pre-specified
and the signal was the development of a line or
colour.
 Overall judgement:
▪ If a study was not reporting results from
automated assays and it did not explicitly
mention blinding then tests were automatically
rated as high risk.
▪ If there was blinding and the second question
was answered with ‘yes’, overall judgement was
‘low’.
2b. Concerns regarding applicability: this concerns the
extent to which the index test evaluated is representative
of the tests that will be used in practice.
 Are there concerns that the index test, its
application or interpretation deviate from the review
question?
▪ All in-house tests were automatically rated as
‘high concern’.
▪ If serum or plasma samples not blood were used
for POC LFIA then tests were automatically
rated high concern
Risk of bias and concerns regarding applicability were
assessed for each test separately.
3. Reference standard
3a. Risk of bias, signalling questions
 Is the reference standard likely to correctly classify
the target condition?
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▪ Assumption: This will likely be the case for case-
control studies that use the ‘correct’ case
definitions
▪ This is also likely for cross-sectional studies
which use the ‘correct’ case definitions.
 Were the reference standard results interpreted
without knowledge of the results of the index test?
▪ Assumption: This will likely be the case for most
case-control studies, but only if serology was not
part of the case definition.
▪ For cross-sectional studies, this should be
explicitly stated.
 Overall judgement risk of bias:
▪ Case-control studies with clear case definitions
were rated as having a ‘low’ risk of bias.
▪ case-control studies with unclear/wrong case
definitions rated as ‘unclear’ Or ‘high risk’ of bias
respectively
▪ Cross-sectional studies with a clear case
definition and the second question answered
with ‘yes’: low risk of bias.
▪ Otherwise ‘unclear’.
3b. Concerns regarding applicability: Are there concerns
that the target condition as defined by the reference
standard does not match the review question?
▪ If serology is included in the case definition, there is
an incorporation bias and thus a high risk of bias.
▪ If a case-control study uses clear criteria and does not
include serology in these criteria: ‘low’ concern of bias.
4. Risk of bias regarding flow and timing, signalling
questions
 Was there an appropriate interval between index
test(s) and reference standard?
▪ We expected that studies with a cross-sectional
design conducted most tests on a date
sufficiently close to the final diagnosis. If we had
reason to suspect that the patient status changed
between the time of testing and the time of
diagnosis, we rated this as ‘no’.
▪ For case-control studies, this was always rated as
‘no’, because serology was always determined
after the case definitions were defined,
sometimes with a long delay.
 Did patients receive the same reference standard?
 Were all patients included in the analysis?
▪ This was rated ‘no’ for all case-control studies.
 Overall judgement:
▪ Case-control studies were always rated as having
a high risk of bias.
▪ For cross-sectional studies, we perceived a low
risk of bias if all three questions were answered
with ‘yes’; a high risk of bias was perceived if at
least one of them was answered ‘no’. All other
possibilities were rated as ‘unclear’ [65].
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